Back to search results

Immune Defense Protein for Upper Respiratory Symptoms in Older Adults

This study is looking at how a dietary supplement called Immune Defense Protein (IDP) affects common cold and flu symptoms in people aged 60 and older. Researchers want to see if IDP, given in either a 50mg or 200mg dose, can reduce how often you get upper respiratory symptoms (like coughing or sneezing), how long they last, and how severe they are. You might be able to join if you are 60 or older, experience cold/flu symptoms at least 2-3 times during the season, and can use a smartphone app. The study is currently unclear on its recruitment status.

Study design
This is a decentralized observational study involving 300 participants. Participants will receive either a 50mg dose of IDP, a 200mg dose of IDP, or a matching placebo (an inactive substance).
What's involved
You will use a personal smartphone device and the Chloe by People Science app to complete self-reported measures and questionnaires at home. The primary endpoint is measured at 17 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for symptom impact is measured at 17 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07431840

Immune Defense Protein Impact On Respiratory Immune Outcomes

Recruiting
NAAges 60+InterventionalSupportive care
Quantec Ltd
~300 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:Immune Defense Protein 50mg DoseIDP 200mg DoseMatching Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Impact on Upper Respiratory Symptom Incidence, Duration and Severity
Measured over 17 weeks

Conditions

Upper Respiratory Disease
Influenza
Viral Upper Respiratory Infection

Explore related trials

InfluenzaPneumoniaUpper Respiratory Tract Infection

Where it's being run

1 sites across 1 states
California1

Who to contact

Noah Craft, M.D., Ph.D
[email protected]
213-328-0919
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

HIV/AIDS
Chronic hepatitis B or C (advanced stages)
Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
Leukemia (e.g., AML, ALL, CLL)
Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
Multiple Myeloma
Any metastatic cancer receiving chemotherapy
Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
mTOR inhibitors (e.g., sirolimus)
JAK inhibitors (e.g., tofacitinib)
Chemotherapy or radiation therapy
Anti-rejection meds post-organ transplant D. Transplant Patients
Solid organ transplant (kidney, liver, heart, lung)
Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
Rheumatoid Arthritis
Systemic Lupus Erythematosus (SLE)
Psoriasis or Psoriatic Arthritis
Inflammatory Bowel Disease (Crohn's disease, Ulcerative colitis)
Multiple Sclerosis (especially on disease-modifying therapies) 3. Other Concomitant Conditions and Therapies:

What this trial measures

  • Impact on Upper Respiratory Symptom Incidence, Duration and Severity17 weeks

    To evaluate the impact of IDP® Preventative Supplementation on incidence of upper respiratory symptoms, and the duration and severity of any symptoms that occur by measuring the change in incidence of upper respiratory symptoms (frequency, type, duration and severity) between study product and placebo groups. Baseline will be compared as well.